SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vasomedical Inc.
VASO 0.170+6.3%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Lotozo who wrote (639)11/9/1997 9:20:00 PM
From: Preston Lurie  Read Replies (1) of 1605
 
All I can say is I've seen it work for one patient. Now of course my experience is whats called anecdotal, that is without scientific merit from a statistical or methodilogical approach. The bottom line of the abstract is what 'scientific' study has proved..."In conclusion, MUST-EECP
demonstrates both the safety and efficacy of
EECP in treating myocardial ischemia in pts
with severe CAD, many of whom had failed
prior CA bypass surgery and/or angioplasty"

Translated that there is now a new therapy (NONINVASIVE) for difficult coronary artery disease(heart blockage) patients. To me this is great both as a doc and investor. The way I see it we haved proven safety and efficacy in the hardest group, now further studies or data from this study(I hope) can prove effectiveness for less sick patients, thus larger patient group.

Also with the PUSH FOR NATURAL TREATMENTS IN OUR society this is a breakthrough for this disease, which is one of the greatest cause for $$ spent by insurers of any condition, think about it.

OF COURSE that may mean nothing long term for vaso or it may!?

P
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News